PROVIDENCE – EpiVax Inc. and CUBRC Inc. have been awarded a two-year, $1 million federal contract from the U.S. Food and Drug Administration to establish best practices and procedures for assessing generic peptides and related impurities for immunogenic potential, EpiVax announced Tuesday. EpiVax CEO and Chief Science Officer Dr. Anne S. De Groot told PBN…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.